India, Nov. 11 -- Zydus Lifesciences Limited has received approval from China's National Medical Products Administration (NMPA) for its Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths.
The medication is indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). It works by restoring the balance of serotonin and norepinephrine in the brain, helping improve mood and alleviate anxiety symptoms.
The capsules will be manufactured at Zydus' Moraiya facility in Ahmedabad, and this marks the company's first-ever approval from China's NMPA, representing a key milestone in its global expansion efforts.
Published by HT Digital C...